Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

NCT03934684 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Refractory Multiple Myeloma

Interventions

DRUG: Drug: Carfilzomib + Dexamethasone
DRUG: Drug: Carfilzomib + Lenalidomide + Dexamethasone

Sponsor

Amgen